Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
Charles River Laboratories International, Inc. logo

NASDAQ · CRL

Charles River Laboratories International, Inc.

Healthcare · Medical - Diagnostics & Research

$359.41

Down-$16.69 (-4.44%)

Updated Nov 2, 2026, 12:25 AM

SID Score

6.7/10

Composite research score

Smart Money

54/100

Neutral

Market cap
9.57B
P/E ratio
-137.99
Dividend yield
0.00%
52-week range
$146.20 – $379.63
Volume
1.5M
Avg. volume
1.03M

Price performance · CRL

CRL price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

CRL closed at $359.41 after 20 trading sessions, up 15.65% for the selected period.

Last close
$359.41
Period change
+15.65%
Period low
$298.00
Period high
$376.10
Daily close
View OHLC price history
CRL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$372.99$374.56$351.98$359.411.5M
Oct 29, 2026$375.00$379.63$368.63$376.10887.34K
Oct 28, 2026$360.01$378.23$360.01$373.981.3M
Oct 27, 2026$351.95$359.89$351.95$358.841.16M
Oct 26, 2026$347.59$357.77$345.89$357.271.18M
Oct 23, 2026$337.78$347.195$332.17$345.37822.3K
Oct 22, 2026$341.43$351.21$337.78$339.662.66M
Oct 21, 2026$313.83$348.95$313.83$344.872.75M
Oct 20, 2026$308.84$317.59$304.00$315.451.27M
Oct 19, 2026$303.33$305.99$297.56$300.02506.63K
Oct 16, 2026$306.09$308.83$296.3537$300.15674.59K
Oct 15, 2026$301.81$309.475$295.40$306.24928.44K
Oct 14, 2026$297.53$310.53$296.00$302.00941.77K
Oct 13, 2026$301.00$302.77$295.15$299.02753.33K
Oct 12, 2026$301.80$303.10$299.2718$301.86543.77K
Oct 9, 2026$294.60$305.205$294.60$301.79679.86K
Oct 8, 2026$297.01$298.27$288.425$298.001.18M
Oct 7, 2026$303.38$305.18$294.28$300.301.24M
Oct 6, 2026$319.80$333.295$300.01$304.961.92M
Oct 5, 2026$292.05$312.26$292.02$310.771.31M

Latest CRL news

The latest Smart Investors Daily articles mentioning CRL.

Stock researchCompany · Overview

CRL research

Overview

Company profile and research snapshot.

Company profile

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$191.50
Implied upside
—
Analysts
22
CRL recent ratings
DateFirmRatingTarget
Oct 13, 2026Morgan StanleyOverweight—
Sep 30, 2026UBSBuy—
Sep 28, 2026JefferiesBuy—
Sep 25, 2026Deutsche BankBuy—
Sep 25, 2026Evercore ISI GroupOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 30, 2026

Charles River (CRL) Stock Could Be 27% Overvalued As Preclinical FDA Collaboration Starts

Charles River Laboratories International has become a talking point after a sharp multi‑year rally, which naturally raises a harder question for you as an investor: Is the current share price still grounded in the cash flows the business can generate, or has enthusiasm run ahead of what those cash streams can reasonably support? Over the past 3 years the stock has returned 115.3%, which puts real pressure on the idea that the present valuation is still aligned with what the underlying cash...

Yahoo · Oct 30, 2026

Charles River Laboratories (CRL) Expands Virtual Control Group Use In Toxicology Studies

Charles River Laboratories International (NYSE:CRL) agreed to deploy its Virtual Control Group database for Ipsen to support toxicology studies and reduce animal use. The Ipsen collaboration uses AI powered analytics and historical control data to replace some live control groups in preclinical testing. Charles River also partnered with Labcorp and the US Food and Drug Administration on methodologies to assess medicine abuse potential using shared data resources. These Virtual Control Group...

Yahoo · Oct 29, 2026

Labcorp Holdings (LH) Expands HPV Testing While Teaming With Regulators On Drug Safety

Labcorp Holdings (NYSE: LH) partnered with Waters Corporation to deploy the BD Onclarity HPV Assay across its national laboratory network. The BD Onclarity HPV Assay rollout is designed to broaden access to advanced cervical cancer screening for patients across the United States. Labcorp announced a collaboration with the FDA and Charles River Laboratories to refine methods used to evaluate drug abuse potential. These moves on BD Onclarity HPV testing and drug abuse potential assessment only...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By